24 results
424B5
SAVA
Cassava Sciences Inc
21 Nov 22
Prospectus supplement for primary offering
8:00am
conditions and negotiations between us, Wainwright and prospective investors. Wainwright will have no authority to bind us by virtue of the engagement letter … , including liabilities under the Securities Act and liabilities arising from breaches of representations and warranties contained in our engagement letter
424B5
SAVA
Cassava Sciences Inc
29 Jul 22
Prospectus supplement for primary offering
4:15pm
and prospective investors. Wainwright will have no authority to bind us by virtue of the engagement letter. We have entered into a securities purchase … , including liabilities under the Securities Act and liabilities arising from breaches of representations and warranties contained in our engagement letter
424B5
2bl9fmm3pk
12 Feb 21
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
qgw 29hrv
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
EX-99.1
0k4knbbl4t f6w
14 Sep 20
Regulation FD Disclosure
4:01pm
8-K
EX-99.1
rv1jw2w71v33
12 Aug 20
Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business Review
8:30am
8-K
EX-99.2
cq0dj r96ttvzvakir
3 Jun 20
Regulation FD Disclosure
5:29pm
8-K
EX-99.1
hro289
6 Dec 19
Regulation FD Disclosure
4:40pm
8-K
EX-99.2
2yyus0332
6 Dec 19
Regulation FD Disclosure
4:40pm
8-K
EX-99.1
bd17dmrdn
29 Oct 19
Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results
8:29am
8-K
EX-99.1
kc6l6ytkvp gvdr
4 Oct 18
Regulation FD Disclosure
5:24pm
424B5
a0ustdi9j7wqb4pe
17 Aug 18
Prospectus supplement for primary offering
12:45pm